Leuprorelin acetate + Sintilimab
NSFC-32230037
Unknown small_molecule active
Quick answer
Leuprorelin acetate + Sintilimab for NSCLC, Stage III is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- NSCLC, Stage III
- Phase
- Unknown
- Modality
- small_molecule
- Status
- active